Browse the corpus

REFERENCES Devos D, “Patient Profile, Indications, Efficacy and Safety of Duodenal Levodopa Infusion in Advanced Parkinson’s Disease,” Mov Disord , 2009, 24(7):993-1000. [PubMed 19253412 ] Factor SA, “Current Status of Symptomatic Medical Therapy in Parkinson’s Disease,” Neurotherapeutics , 2008, 5(2):164-80. [PubMed 18394561 ] Molina JA, Sàinz-Artiga MJ, Fraile A, et al, “Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,” Mov Disord , 2000, 15(5):869-72. [PubMed 11009192 ] Olanow CW, Watts RL, and Koller WC, “An Algorithm (Decision Tree) for the Management of Parkinson's Disease (2001): Treatment Guidelines,” Neurology , 2001, 56(11 Suppl 5):1-88. [PubMed 11402154 ] Silber MH, Ehrenberg BL, Allen RP, et al, “An Algorithm for the Management of Restless Legs Syndrome,” Mayo Clin Proc , 2004, 79(7):916-22. [PubMed 15244390 ] Stern MB, “Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,” Neurology , 1997, 49(1 Suppl 1):2-9. [PubMed 9222162 ] Walker SW, Fina A, and Kryger MH, “L-Dopa/Carbidopa for Nocturnal Movement Disorders in Uremia,” Sleep , 1996, 19(3):214-8. [PubMed 8723378 ] Weintraub D, Siderowf AD, Potenza MN, et al, “Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,” Arch Neurol , 2006, 63(7):969-73. [PubMed 16831966 ] Vignatelli L, Billiard M, Clarenbach P, et al, “EFNS Guidelines on Management of Restless Leg Syndrome and Periodic Limb Movement Disorder in Sleep,” Eur J Neurol , 2006, 13(10):1049-65. [PubMed 16987157 ] Topic 8994 Version 41.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]